ZA986480B - Therapeutic and dietary compositions - Google Patents

Therapeutic and dietary compositions

Info

Publication number
ZA986480B
ZA986480B ZA986480A ZA986480A ZA986480B ZA 986480 B ZA986480 B ZA 986480B ZA 986480 A ZA986480 A ZA 986480A ZA 986480 A ZA986480 A ZA 986480A ZA 986480 B ZA986480 B ZA 986480B
Authority
ZA
South Africa
Prior art keywords
therapeutic
compositions
dietary compositions
nutrition
therapy
Prior art date
Application number
ZA986480A
Other languages
English (en)
Inventor
David Frederick Horrobin
Hans-Jurgen Tritschler
Original Assignee
Scotia Pharma Ltd
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10816266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA986480(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scotia Pharma Ltd, Asta Medica Ag filed Critical Scotia Pharma Ltd
Publication of ZA986480B publication Critical patent/ZA986480B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
ZA986480A 1997-07-22 1998-07-21 Therapeutic and dietary compositions ZA986480B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9715444A GB9715444D0 (en) 1997-07-22 1997-07-22 Therapeutic and dietary compositions

Publications (1)

Publication Number Publication Date
ZA986480B true ZA986480B (en) 1999-01-22

Family

ID=10816266

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA986480A ZA986480B (en) 1997-07-22 1998-07-21 Therapeutic and dietary compositions

Country Status (31)

Country Link
US (1) US6630157B1 (xx)
EP (2) EP1419769A1 (xx)
JP (1) JP4476479B2 (xx)
KR (1) KR100545630B1 (xx)
CN (2) CN1198608C (xx)
AT (1) ATE262900T1 (xx)
AU (1) AU739876B2 (xx)
BG (1) BG64349B1 (xx)
BR (1) BR9812102A (xx)
CA (1) CA2297082C (xx)
CZ (1) CZ298527B6 (xx)
DE (1) DE69822832T2 (xx)
DK (1) DK0994705T3 (xx)
ES (1) ES2214717T3 (xx)
GB (2) GB9715444D0 (xx)
HK (1) HK1029281A1 (xx)
HU (1) HU226673B1 (xx)
IL (2) IL134090A0 (xx)
MY (1) MY127930A (xx)
NO (1) NO327173B1 (xx)
NZ (1) NZ502278A (xx)
PL (1) PL194059B1 (xx)
PT (1) PT994705E (xx)
RO (1) RO121318B1 (xx)
RU (1) RU2205004C2 (xx)
SK (1) SK285836B6 (xx)
TR (1) TR200000178T2 (xx)
TW (1) TW565444B (xx)
UA (1) UA66363C2 (xx)
WO (1) WO1999004782A1 (xx)
ZA (1) ZA986480B (xx)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
DE10027968A1 (de) * 2000-06-08 2001-12-13 Asta Medica Ag Mittel zur Therapie von Demenzen
US20020132781A1 (en) * 2000-10-06 2002-09-19 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor
US8669282B2 (en) * 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
NZ539624A (en) * 2002-09-27 2008-08-29 Martek Biosciences Corp Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
WO2004028469A2 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Docohexaenoic acid for improved glycemic control
DE60332958D1 (de) * 2002-11-04 2010-07-22 Ocean Nutrition Canada Ltd Mikrokapseln mit mehrfachen hüllen und verfahren zu deren herstellung
US20060233863A1 (en) 2003-02-10 2006-10-19 Enzymotec Ltd. Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy
CA2515368A1 (en) 2003-02-13 2004-08-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
US8633246B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
EP1656130B1 (en) * 2003-08-11 2008-07-30 Hill's Pet Nutrition Inc. Omega-3 fatty acids for the treatment of canine ostheoarthritis
CH698539A8 (de) 2003-08-18 2009-10-15 Btg Int Ltd Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose.
WO2005095959A2 (en) * 2004-03-29 2005-10-13 Howard Murad Methods for treating dermatological conditions in a patient
NZ553263A (en) 2004-07-19 2010-06-25 Biocon Ltd Insulin-oligomer conjugates, formulations and uses thereof
WO2006016363A2 (en) 2004-08-10 2006-02-16 Enzymotec Ltd. Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0428166D0 (en) * 2004-12-23 2005-01-26 Efamol Ltd Use of essentially fatty acid molecules
US8034450B2 (en) * 2005-01-21 2011-10-11 Ocean Nutrition Canada Limited Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof
WO2006109194A2 (en) * 2005-01-27 2006-10-19 Ocean Nutrition Canada Ltd. Chromium-fatty acid compounds and methods of making and using thereof
DE602006011127D1 (de) * 2005-01-27 2010-01-28 Ocean Nutrition Canada Ltd Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
US9968120B2 (en) * 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
US20070082063A1 (en) * 2005-10-11 2007-04-12 Douglas Bibus Risk assessment and correction of membrane damage of the upper GI tract
WO2007064871A2 (en) * 2005-12-02 2007-06-07 Howard Murad Diagnostic and treatment regimen for achieving body water homeostasis
WO2007089685A2 (en) * 2006-01-30 2007-08-09 University Of Georgia Research Foundation Compositions and methods for inducing adipose tissue cell death
WO2007120500A2 (en) * 2006-04-07 2007-10-25 Ocean Nutrition Canada Ltd. Emulsions and microcapsules with substances having low interfacial tension, methods of making and using thereof
KR101994513B1 (ko) * 2006-06-05 2019-06-28 디에스엠 뉴트리셔널 프라덕츠 아게 개선된 쉘을 가지는 마이크로캡슐
NZ578872A (en) 2007-01-10 2012-07-27 Ocean Nutrition Canada Ltd Vegetarian microcapsules
DE102007038849A1 (de) 2007-08-16 2009-02-19 Adscil Gmbh Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie
WO2009050738A2 (en) 2007-10-16 2009-04-23 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US9119826B2 (en) * 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US9220702B2 (en) 2011-05-12 2015-12-29 Nippon Suisan Kaisha, Ltd. Composition for external use on skin for inflammatory diseases
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2014151128A1 (en) * 2013-03-15 2014-09-25 Andrade Agustin Composition and method for treating neuropathy
US9241923B2 (en) 2013-07-16 2016-01-26 Mead Johnson Nutrition Company Methods for promoting neuronal development and/or health
US9226914B2 (en) * 2013-07-16 2016-01-05 Mead Johnson Nutrition Company Methods for promoting neuronal development and/or health
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
CN105814209B (zh) 2013-12-04 2022-02-25 日本水产株式会社 含有二高-γ-亚麻酸的微生物油和含有二高-γ-亚麻酸的微生物生物质
WO2015185698A1 (en) * 2014-06-04 2015-12-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same
WO2016044167A1 (en) * 2014-09-15 2016-03-24 Abbott Laboratories Methods for increasing muscle strength and mobility in subjects experiencing significant physical inactivity using gamma linolenic acid
CN113896628A (zh) 2015-05-13 2022-01-07 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
WO2017013492A1 (en) 2015-07-21 2017-01-26 Dignity Sciences Limited Compositions comprising 15-hepe for use in treating or preventing cancer and neurologic disease
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
WO2022140279A1 (en) * 2020-12-22 2022-06-30 Buck Institute For Research On Aging Synergistic modulators of alpha-dicarbonyl detoxification and their use for inducing weight loss and the treatment of diabetic pathologies
CN114533715A (zh) * 2022-01-28 2022-05-27 上海市肺科医院 一种针对sting靶点的小分子抑制剂及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1176916B (it) * 1984-10-10 1987-08-18 Elvira Pistolesi Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
GB8524275D0 (en) 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
LU86220A1 (de) * 1985-12-19 1987-07-24 Chimicasa Gmbh Verfahren zur herstellung eines den cholesterin-und triglyceridgehalt senkenden pharmazeutischen praeparates
DE3615710A1 (de) * 1986-05-09 1987-11-26 Hoechst Ag Zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaeuren in biologischen systemen
US4937265A (en) * 1987-05-28 1990-06-26 Teijin Limited Antidiabetic method comprising 7-thiaprostaglandin E1 or its derivatives
EP0382066A3 (de) * 1989-02-09 1992-01-08 ASTA Medica Aktiengesellschaft Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
US5602183A (en) 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
DE4229914A1 (de) 1992-09-08 1994-03-10 Basf Ag Verbessertes Verfahren zur Herstellung von R/S-Ï-Liponsäure oder R/S-â-Liponsäure
DK0661051T3 (da) 1993-10-11 2006-05-22 Viatris Gmbh Medikament til behandling af hypertension
US5472698A (en) * 1994-12-20 1995-12-05 Elizabeth Arden Co., Division Of Conopco, Inc. Composition for enhancing lipid production in skin
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
EP1021177A4 (en) * 1997-02-04 2002-05-15 John V Kosbab COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment

Also Published As

Publication number Publication date
AU739876B2 (en) 2001-10-25
RO121318B1 (ro) 2007-03-30
ES2214717T3 (es) 2004-09-16
CN1198608C (zh) 2005-04-27
IL134090A0 (en) 2001-04-30
GB2327347A (en) 1999-01-27
DE69822832T2 (de) 2004-08-12
US6630157B1 (en) 2003-10-07
CN1265032A (zh) 2000-08-30
DK0994705T3 (da) 2004-08-02
HUP0002701A3 (en) 2001-03-28
PL194059B1 (pl) 2007-04-30
CZ2000229A3 (en) 2001-05-16
PT994705E (pt) 2004-08-31
BR9812102A (pt) 2000-07-18
CZ298527B6 (cs) 2007-10-24
AU8451998A (en) 1999-02-16
NO20000303L (no) 2000-03-16
RU2205004C2 (ru) 2003-05-27
ATE262900T1 (de) 2004-04-15
MY127930A (en) 2006-12-29
CA2297082A1 (en) 1999-02-04
GB9816020D0 (en) 1998-09-23
JP2001510799A (ja) 2001-08-07
NO327173B1 (no) 2009-05-04
HUP0002701A1 (hu) 2001-01-29
DE69822832D1 (de) 2004-05-06
GB9715444D0 (en) 1997-09-24
HK1029281A1 (en) 2001-03-30
CN1679532A (zh) 2005-10-12
IL134090A (en) 2006-08-20
EP0994705A1 (en) 2000-04-26
BG64349B1 (bg) 2004-11-30
JP4476479B2 (ja) 2010-06-09
KR100545630B1 (ko) 2006-01-24
TW565444B (en) 2003-12-11
CA2297082C (en) 2008-04-22
SK842000A3 (en) 2001-02-12
GB2327347B (en) 2000-10-04
BG104141A (bg) 2000-10-31
PL338219A1 (en) 2000-10-09
NZ502278A (en) 2002-02-01
EP0994705B1 (en) 2004-03-31
EP1419769A1 (en) 2004-05-19
HU226673B1 (en) 2009-06-29
WO1999004782A1 (en) 1999-02-04
UA66363C2 (uk) 2004-05-17
TR200000178T2 (tr) 2000-08-21
KR20010022148A (ko) 2001-03-15
NO20000303D0 (no) 2000-01-21
SK285836B6 (sk) 2007-09-06

Similar Documents

Publication Publication Date Title
GB2327347B (en) Therapeutic and dietary compositions
PT1251750E (pt) Formula pediatrica melhorada e metodos para proporcionar nutricao e melhorar a tolerancia
CA2231292A1 (en) Method for decreasing ldl-cholesterol concentration and increasing hdl-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
EP0211354A3 (en) Nucleosides and their use as antineoplastic agents
HK1028957A1 (en) Use of n,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of chronic pain
ATE238805T1 (de) Multifunktionelle formulierung für fettabsorbierung und zur senkung des cholesterolgehaltes im blut, welche chitosan und nicotinsäure enthält
ZA895840B (en) N-2,3-butadienyl tri-and tetraaminoalkane derivatives
AU652988B2 (en) Method for insuring adequate intracellular glutathione in tissue
ES8707488A1 (es) Un metodo para preparar maleato de 2-terc-butilamino-3'-cloropropiofenona
AU6207196A (en) Composition and method for treating prostate cancer
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
EP0190860A3 (en) 6-chloro-3-methyl-1h-2,3,4,5-tetrahydro-3-benzazepine-n-oxide and medical compositions using it
SU1630043A1 (ru) Плазмозамещающий раствор для лечения шока "мафусол"
ES8706665A1 (es) Procedimiento de preparar nuevas sales de acidos carboxilicos, terapeuticamente utiles
UA28900A (uk) Спосіб лікування хворих на хронічний гастрит зі збереженою і підвищеною секреторною та кислотоутворювальною функцією шлунка
RU94004904A (ru) Средство для лечения лейкозов и способ лечения лейкозов
SU1807595A1 (ru) Средство для лечения отравлений ртутью
BG101692A (en) Means for the prophylaxy and treatment of iodine-deficiency states
GR1002968B (el) Φαρμακευτικο παρασκευασμα βασιζομενο σε εναιωρημα εμβρυικων κυτταρων με ανοσοδιορθωτικη δραση και μεθοδος θεραπειας ζαχαρωδους διαβητη με τη χρηση αυτου του παρασκευασματος.
AU5826886A (en) Carboxy azetidine derivatives for use in the reduction of blood cholesterol levels
TH16764A (th) การรักษาโรคเบาหวานโดยการให้ ไมโอ-ไอโนซิทอล
UA31177A (uk) Спосіб лікування нейросенсорної приглухуватості
UA8273A (uk) Спосіб лікування опіків при багатофакторному пошкодженні
MD2259G2 (ro) Metodă de tratament al spondiloartralgiei autoimune la copii